Developed By Name Signature Date
|
|
- Mitchell Henderson
- 5 years ago
- Views:
Transcription
1 Patient Group Direction 2210 version 1.0 Supply of Dexamethasone for the Prevention of Chemotherapy Induced Nausea and Vomiting by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction: October 2017 Review Date: September 2019 Developed By Name Signature Date Physician Pharmacist Lead Professional Lead Pharmacist for Cancer Services Cancer & Vascular Access Advanced Nurse Practitioner Note: The Lead Professional is responsible for ensuring the co-ordination, composition, consultation, revision and distribution of the PGD to practitioners who will be using the PGD as well as ensuring that the PGD is no longer used if becomes out of date and once it has expired. The Clinical Effectiveness Department will write to the Lead Professional approximately 4 months before the review date as a reminder that a review is required. Ratified on behalf of: TORBAY AND SOUTH DEVON NHS FOUNDATION TRUST Medicines Management Committee Chair Signed: Name: Clinical Director Pharmacy and Prescribing Date: Lead Officer Signed: Name: Medical Director Date: October 2017 September 2019 Page 1 of 8
2 Patient Group Direction 2210 version 1.0 Supply of Dexamethasone for the Prevention of Chemotherapy Induced Nausea and Vomiting by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Objective To enable nurses to efficiently prevent and treat chemotherapy induced nausea and vomiting by dispensing Dexamethasone 2mg to be taken TDS reducing by 2mg daily over 3 days. 1. Clinical Condition Definition of condition/situation Patients who receive Chemotherapy are at risk of chemotherapy induced nausea and vomiting. Facilities required Criteria for inclusion Dexamethasone will be kept in a locked drug cupboard as TTA packs on the Ricky Grant Day Unit and Turner Ward. Patients may be included in the PGD if the patient is receiving chemotherapy. Criteria for exclusion Hypersensitivity to Dexamethasone Possible interactions with - Aldesleukin - Rifamycins - Coumarins - Carbamazepine - Fosphenytoin - Phenobarbital - Phenytoin - Primidone - Amphotericin - Caspofungin - Daclatasvir - Simprevir - Indinavir - Lopinavir - Saquinavir - Telaprevir - Rilpivirine - Netupitant - Live Vaccines Action if excluded If receiving chemotherapy and excluded from PGD, refer to medical team on Turner ward or a nonmedical prescriber for assessment. Action if patient refuses medication Document informed refusal in patient s records and action taken: a) Refer to the medical team on Turner Ward or a non-medical prescriber to review the patient. b) Inform the patient s consultant. October 2017 September 2019 Page 2 of 8
3 2. Characteristics of Staff Qualifications required NMC Registered Nurse who has successfully completed the NMC NURB 292 Care of the Patient Requiring Chemotherapy, NURB 360 Enhanced Care of the Patient Requiring Chemotherapy or equivalent course. Additional requirements Working knowledge of Medicines Policy, Anaphylaxis Policy, Consent Policy and Chemotherapy Services SOP. Evidence of continuing professional development and revalidation. Working knowledge of the NMC Standards for Medicines Management 2007, (updated 2010) and other relevant codes of professional practice. 3. Description of Treatment Name of Medicine Supplied Legal Class Storage Dose to be used (including criteria for use of differing doses) Method or route of administration Total dose and number of times drug to be given. Details of supply (if supply made) Dexamethasone POM (Prescription Only Medicine) Locked drug cupboard in the prep room on RGDU and Turner ward. 2 milligrams Oral 2mg to be taken three times daily for 1 day, then 2mg to be taken twice daily for 1 day, then 2mg to be taken as a single dose. Starting the day after chemotherapy. Supply one TTA pack of 6 tablets. Administered from ward stock of TTA packs. Contra-indications Refer to medical practitioner or non-medical prescriber if appropriate or alternative action as indicated by related protocol and document in patient s records Live vaccines Systemic infection October 2017 September 2019 Page 3 of 8
4 Cautions Congestive heart failure. Diabetes mellitus Diverticulitis Congestive heart failure Epilepsy Glaucoma PMH of steroid myopathy PMH of TB Hypertension Hypothyroidism Infection Myasthenia gravis Ocular herpes simplex Osteoporosis Peptic ulcer Psychiatric reactions Recent intestinal anastomoses Recent MI Severe affective disorders Thromboembolic disorders Ulcerative colitis Interactions If patient is taking any other medications consult BNF Appendix 1 for any potential interactions. October 2017 September 2019 Page 4 of 8
5 Potential side-effects and adverse reactions The incidence of predictable undesirable effects, including hypothalamic-pituitary-adrenal suppression, correlates with the relative potency of the drug, dosage, timing of administration and the duration of treatment. Fluid and electrolyte disturbances: Sodium retention, fluid retention, congestive heart failure in susceptible patients, potassium loss, hypokalaemic alkalosis, hypertension, increased calcium excretion. Musculoskeletal effects: Muscle weakness, steroid myopathy, loss of muscle mass, osteoporosis (especially in post-menopausal females), vertebral compression fractures, aseptic necrosis of femoral and humeral heads, pathological fracture of long bones, tendon rupture. Gastro-intestinal: Peptic ulcer with possible perforation and haemorrhage, perforation of the small and large bowel particularly in patients with inflammatory bowel disease, pancreatitis, abdominal distension, ulcerative oesophagitis, dyspepsia, oesophageal candidiasis. Dermatological: Impaired wound healing, thin fragile skin, petechiae and ecchymoses, erythema, striae, telangiectasia, acne, increased sweating, suppressed reaction to skin tests, other cutaneous reactions such as allergic dermatitis, urticaria, angioneurotic oedema. Neurological: Convulsions, vertigo, headache. Increased intracranial pressure with papilloedema (pseudotumour cerebri) may occur usually after treatment. Psychiatric: A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions(including mania, delusions, hallucinations and aggravation of schizophrenia), behavioural disturbances, irritability, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported. Reactions are common and may occur in both adults and children. In adults, the frequency of severe reactions have been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown. Endocrine: Menstrual irregularities, amenorrhoea, development of Cushingoid state, suppression of growth in children and adolescents, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress as in trauma, surgery or illness), decreased carbohydrate tolerance, manifestations of latent diabetes mellitus, hyperglycaemia, increased requirements for insulin or oral hypoglycaemic agents in diabetics, hirsutism. Anti-inflammatory and immunosuppressive effects: Increased susceptibility and severity of infections with suppression of clinical symptoms and signs. Opportunistic infections, recurrence of dormant tuberculosis. Eye disorders: Posterior subcapsular cataracts, increased intra-ocular pressure, papilloedema, corneal or scleral thinning, exacerbation of ophthalmic viral disease, glaucoma, exophthalmos, chorioretinopathy. Metabolic: Negative nitrogen balance due to protein catabolism. Negative calcium balance. Cardiovascular: Myocardial rupture following recent myocardial infarction. Other: Hypersensitivity, including anaphylaxis has been reported, leucocytosis, thromboembolism, weight gain, increased appetite, nausea, malaise, hiccups. Withdrawal symptoms and signs Too rapid a reduction of corticosteroid dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension, and death. In some instances, withdrawal symptoms may simulate a clinical relapse of the disease for which the patient has been undergoing treatment. Management of potential side-effects and adverse reactions Contact the medical team on Turner Ward to review patient. Trust anaphylaxis policy. Unusual or life threatening reactions require immediate medical attention. October 2017 September 2019 Page 5 of 8
6 Advice and information to patient/carer including follow-up Specify method of recording supply /administration including audit trail Unusual or life threatening reactions require immediate medical attention. If symptoms of nausea persist contact the 24 hour chemotherapy telephone triage. The following will be recorded in the patient s records: The diagnosis and treatment The dose and quantity supplied Batch number and expiry date if appropriate The route of administration and site of administration where appropriate The frequency of administration and duration of treatment The time and date of supply/administration The signature and name of the person supplying/administering the medication Document allergies and other adverse drug reactions clearly in patient records and inform the GP and other relevant practitioners/patient/carer for further reporting and action if required. Report any adverse drug reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) through the yellow card reporting system ( 4. Other Information Follow up treatment: Arrangements for medicine supply: Arrangements for medical referral: The patient / carer has access to a 24 hour help line. The patient s level of emesis will be assessed at each chemotherapy appointment. Use ward stock of TTA packs. Junior medical team is available by pager and they are based on Turner Ward. Associate specialist available by pager and is based in Oncology. Consultants can be contacted, or message left, via their secretaries. Lines of accountability: 5. Appendices References used in the development of this PGD: The senior nurse coordinating the shift is accountable. NICE guidance National Institute for Health and Care Excellence, 2013, NICE medicines practice guidelines [MPG2] Patient Group Directions Guidance and guidelines NICE BNF MIMMS Green Book Stockley for Drug Interactions Current SPC (Last Updated on emc 13-July-2017) Department of Health Information Trust Protocols and Documents Local Formularies Audit details Annual snapshot audit of the medical notes October 2017 September 2019 Page 6 of 8
7 Training Clinical condition Chemotherapy induced nausea and vomiting. Medical treatment Management of potential side effects Competency assessment Successful completion of the NMC NURB 292 Care of the Patient Requiring Chemotherapy, NURB 360 Enhanced Care of the Patient Requiring Chemotherapy or equivalent course. Local chemotherapy competency document. Frequency of training / review process Chemotherapy competence to be maintained at yearly intervals by attendance of the CUREP study day. Please refer to the summary of product characteristics for full information This Patient Group Direction is operational from the start of October 2017 and expires end of September 2019 Version History Version Date Brief Summary of Change Owner s Name v 1.0 September New PGD developed by Cancer Services to enable Torbay and South Devon NHS 2017 registered nurses to supply Dexamethasone Foundation Trust For more information on the status of this document, contact: Medicines Governance Team Administrator Pharmacy Department Torbay Hospital tsdft.medicinesgovernance@nhs.net Date of Issue October 2017 Reference PGD 2210 v 1.0 Dexamethasone Path V:medicines governance/pgds/cancer Services/PGD 2210 v1.0 Dexamethasone Oct17-Sept19 October 2017 September 2019 Page 7 of 8
8 Patient Group Direction 2210 version 1.0 Supply of Dexamethasone for the Prevention of Chemotherapy Induced Nausea and Vomiting by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Objective: To enable nurses to efficiently prevent and treat chemotherapy induced nausea and vomiting by dispensing Dexamethasone 2mg to be taken TDS reducing by 2mg daily over 3 days. The individual practitioners named below are authorised to operate within the above PGD, being employees of Torbay and South Devon NHS Foundation Trust CLINICAL AREA LOCATION / DEPARTMENT The following list must be kept with a copy of the PGD in each clinical area using that PGD. Each practitioner will receive and sign for an individual copy of the PGD. Only fully competent, qualified and trained professionals may operate within PGDs. I agree to administer/supply the above preparation in accordance with this Patient Group Direction and I have received an up to date copy of the ratified PGD: NAME (please print) PROFESSIONAL TITLE SIGNATURE AUTHORISING MANAGER (please print) MANAGER S SIGNATURE DATE October 2017 September 2019 Page 8 of 8
9 Document Control Information This is a controlled document and should not be altered in any way without the express permission of the author or their representative. Please note this document is only valid from the date approved below, and checks should be made that it is the most up to date version available. If printed, this document is only valid for the day of printing. Ref No: 2210 Document title: Dexamethasone, Supply of within Cancer Services Purpose of document: Patient Group Direction Date of issue: 6 October 2017 Next review date: 30 September 2019 Version: 1 Last review date: Author: Physician Pharmacist Cancer & Vascular Access Advanced Nurse Practitioner Directorate: Medical Services Equality Impact: The guidance contained in this document is intended to be inclusive for all patients within the clinical group specified, regardless of age, disability, gender, gender identity, sexual orientation, race and ethnicity & religion or belief Committee(s) approving the document: Clinical Director of Pharmacy Trust, Medicines Management Committee Chair Date approved: 28 September 2017 Links or overlaps with other policies: All TSDFT Trust Strategies, policies and procedure documents Does this document have training implications? If yes please state: Please select Yes No Does this document have financial implications? If yes please state: Is this document a direct replacement for another? If yes please state which documents are being replaced: Document Amendment History Date Version no. Amendment summary Ratified by: 6 October New Clinical Director of Pharmacy Trust Medicines Management Committee Chair Collated by Clinical Effectiveness Dexamethasone, Supply of within Cancer Services Document Control Information
Developed By Name Signature Date
Patient Group Direction 2154 version 2.0 Administration / Supply of Prednisolone in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationDeveloped By Name Signature Date
Patient Group Direction 2156 version 2.0 Administration of Ipratropium 250mcg/ml Nebuliser Solution in Acute Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Date of
More informationPatient Group Direction for PREDNISOLONE (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPRESCRIBING INFORMATION
PRESCRIBING INFORMATION Pr FLORINEF (fludrocortisone acetate) 0.1 mg Tablets Mineralocorticoid for adrenal insufficiency Paladin Labs Inc. Date of Preparation: 6111 Royalmount Avenue, Suite 102 May 1,
More informationPRESCRIBING INFORMATION. (betamethasone sodium phoshate) Enema 5 mg/100 ml. Topical Corticosteroid
PRESCRIBING INFORMATION Pr BETNESOL (betamethasone sodium phoshate) Enema 5 mg/100 ml Topical Corticosteroid Paladin Labs Inc. Date of revision: 100 Alexis Nihon Blvd, Suite 600 May 1, 2009 St Laurent,
More informationPatient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services
Patient Group Direction for the supply and/or administration of Ibuprofen 400mg tablets to patients attending NHS Borders services This document authorises the supply and/or administration of Ibuprofen
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Synacthen 250 micrograms/ml solution for injection. Summary of Product Characteristics 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance 250 micrograms of Tetracosactide.
More informationPatient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationPATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF ORAL DIAZEPAM TO WORKING AGE AND OLDER PEOPLE IN THE COMMUNITY Version Number: 5 Patient Group Direction drawn up by: Name Ray Lyon Dr Al Amaladoss
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationGG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationPackage leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone
Package leaflet: Information for the patient Dexametason Abcur 1 mg tablets Dexametason Abcur 4 mg tablets Dexamethasone Read all of this leaflet carefully before you start taking this medicine because
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationINZITAN. Quantitative composition The active substances are: dexamethasone, lidocaine (hydrochloride), thiamine (hydrochloride) and cyanocobalamin.
Read all of this leaflet carefully before you start taking this medicine - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor or your pharmacist.
More informationThis document expires on Patient Group Direction No. VI 11
Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationVersion Number: 5. Patient Group Direction drawn up by: Chief Pharmacist - Strategy. Group direction authorised by:
PATIENT GROUP DIRECTION (PGD) FOR THE INPATIENT ADMINISTRATION OF ORAL LORAZEPAM TO WORKING AGE AND OLDER PEOPLE (includes persons in a Place of Safety suite) Version Number: 5 Patient Group Direction
More informationTHIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
Patient Group Direction for Pneumococcal polysaccharide vaccine VERSION: PNEUMOCOCCAL POLY-2013.1 (Pneumovax II ) Start 1 st May 2013 Expiry 30 th April 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION
PATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG TABLETS FOR THE FIRST-LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION CLASSIFICATION OF DOCUMENT: PURPOSE: Patient Group Direction Document
More informationSALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
SALBUTAMOL INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department
More informationSYNACTHEN DEPOT (tetracosactrin zinc phosphate complex)
1 SYNACTHEN DEPOT (tetracosactrin zinc phosphate complex) DESCRIPTION Tetracosactrin is the first corticotrophic preparation to be produced entirely by synthesis and displays all the pharmacological properties
More informationSAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationThis document expires on Patient Group Direction No. VI 5
Patient Group Direction (PGD) for The Administration of Combined Adsorbed Diphtheria, Tetanus, Pertussis, (Acellular Component) and Inactivated Poliomyelitis Vaccine (Infanrix-IPV ) to children aged between
More informationExpiry Date: September 2009 Template Version: Page 1 of 7
GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationThis document expires on Patient Group Direction No. VI 7
Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationClinical Condition Indication:
GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationpatient group direction
NAPROXEN v01 1/10 NAPROXEN PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationPATIENT GROUP DIRECTION (PGD)
PATIENT GROUP DIRECTION (PGD) SUPPLY OF NALOXONE HYDROCHLORIDE INJECTION BY REGISTERED NURSES TO CLIENTS BEING RELEASED FROM HMP FORD Version Number: 01HMP Patient Group Direction originally drawn up by:
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OR ADMINISTRATION OF LEVONORGESTREL 1500 MICROGRAM TABLET (e.g LEVONELLE 1500 ) PGD
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorized by their organization to practice under it. The most recent and in date final signed version
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Hydrocortisone 20 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg - Each tablet contains 20 mg of hydrocortisone. For the
More informationPATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (Champix ) BY COMMUNITY PHARMACISTS Version No: Draft 2 Please note this PGD has been approved by SWYFT Drugs and Therapeutic Committee this is an
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory EFCORLIN SOLUBLE
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory EFCORLIN SOLUBLE Hydrocortisone Sodium Succinate injection IP 100 mg QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial
More informationGG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationExpiry Date: July 2009 Template Version: Page 1 of 7
Salbutamol nebules YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT NPGD2007/355 (supersedes 2004/177) Clinical Condition Indication: Inclusion
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION Supply / Administration of: By: Pharmacists Azithromycin 250mg capsules for Chlamydia In: Community Pharmacy It is the responsibility of the professional working under this PGD
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the Supply of Salbutamol Inhaler to patients receiving treatment from NHS Borders Emergency Department/Out of Hours/Minor Injury Units This document authorises the supply or
More informationSYNACTHEN DEPOT i.m. tetracosactide hexaacetate
SYNACTHEN DEPOT i.m. tetracosactide hexaacetate 1 mg/ml suspension for injection New Zealand Consumer Medicine Information What is in this leaflet Read all of this leaflet carefully before you are given
More informationCommunity Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationPharmacokinetics Absorption Prednisolone is readily and almost completely absorbed from the GI tract after oral administration.
PREDNITAB Composition Prednitab 5 Tablets Each tablet contains Prednisolone 5 mg. Tablets Prednitab 20 Tablets Each tablet contains Prednisolone 20 mg. Action Prednisolone is a synthetic glucocorticoid
More informationpatient group direction
CYCLIZINE v01 1/7 CYCLIZINE PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationPATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)
PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) VALID FROM: 1 st July 2016 REVIEWED DATE: 30 th June 2019 This
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: Medicines Procedure: Patient Group Directions for the Administration of Hepatitis B Vaccine for SABP Drug and Alcohol Teams. PURPOSE OF PROCEDURE:
More informationNHS Lothian Patient Group Direction PGD Number: 437 Version: 02. Title: Doxycycline: Chlamydia Sexual Health Services
PATIENT GROUP DIRECTION FOR THE SUPPLY OF DOXYCYCLINE FOR TREATMENT OF CHLAMYDIA, CONTACTS OF CHLAMYDIA OR CONTACTS OF NON-GONOCOCCAL URETHRITIS (NGU) PRESENTING WITH TREATMENT VOUCHER TO COMMUNITY PHARMACISTS
More informationpatient group direction
ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationThis document expires on Patient Group Direction Number VI 19
Patient Group Direction (PGD) for The Administration of Pneumococcal Polysaccharide Vaccine (PPV, Pneumovax II ) to adults over 65 years and at risk groups aged 2 years and over, by Registered Nurses employed
More informationPatient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02
More informationPatient Group Direction for PROCHLORPERAZINE (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPatient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018
Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start 1 st July 2015 Expiry 30 th June 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: BLACKPOOL
More informationAction Dexamethasone is a synthetic corticosteroid (glucocorticoid). As such, its main actions may be grouped as follows:
DECORT Composition Decort 0.5 mg Tablets Each tablet contains Dexamethasone 0.5 mg. Tablets Decort 0.75 mg Tablets Each tablet contains Dexamethasone 0.75 mg. Decort 2 mg Tablets Each tablet contains Dexamethasone
More informationPATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN TAYSIDE GENERAL POLICY 2 PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE 4 STANDING ORDER
More informationClinical Condition Indication:
Patient Group Direction ( for Health Care GG&C PGD ref no: 2018/1611 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition
More informationPatient Group Directions Policy
Patient Group Directions Policy Category: Summary: Equality Analysis undertaken: Valid From: Date of Next Review: Approval Date/ Via: Distribution: Related Documents: Author(s): Further Information: This
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationSAMPLE. This direction was authorised on 4/5/2007. The direction will be reviewed by 4/5/2009
Patient Group Direction for the Supply and Administration of Flumazenil 100microgram Injection To Patients requiring reversal of oversedation due to midazolam in association withendoscopy attending Endoscopy
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) Or Adsorbed DIPHTHERIA/TETANUS/acellular
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Prednesol 5mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg of prednisolone as Prednisolone Sodium Phosphate.
More informationPatient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine
n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine
More informationPATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets. By: Accredited Pharmacists
PATIENT GROUP DIRECTION for the Supply of: Varenicline (Champix ) tablets By: Accredited Pharmacists In: Community Pharmacies in [insert area] accredited by [insert council] It is the responsibility of
More informationPatient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationCLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )
Patient Group Direction for Pneumococcal Conjugate Vaccine (Prevenar 13 ) Version: PNEUMOCOCCAL CONJUGATE 2014.1 Start 1 st February 2014 Expiry 31 st January 2017 THIS PATIENT GROUP DIRECTION HAS BEEN
More informationPatient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015
Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS-2013. 1 (Rotarix ) Start 1 st July 2013 Expiry 30 th June 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationSupply of Clarithromycin by Community Pharmacists to Patients with an Exacerbation of COPD Protocol No: 300 Version 2
Supply of Clarithromycin by Community Pharmacists to Patients with an Exacerbation of COPD Protocol No: 300 Version 2 Date protocol prepared: April 2010 Date protocol due for review: April 2012 This patient
More informationpatient group direction
DIAZEPAM v01 1/9 DIAZEPAM PGD Details Version 1.0 Legal category Staff grades Approved by CD Benz POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More information08-15 ORADEXON ORGANON
08-15 ORADEXON ORGANON 1. NAME OF THE MEDICINAL PRODUCT Oradexon Organon injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains 5.25 mg or 5 mg of the glucocorticoid dexamethasone sodium
More informationGG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against rotavirus.
More informationSOMATROPIN ( Genotropin, Humatrope, Norditropin,
Shared Care Guidelines DRUG: SOMATROPIN ( Genotropin, Humatrope, Norditropin, Saizen and Omnitrope ) (Adults) Introduction: Indication: Growth hormone deficiency in adults Dosage & administration: 150-300
More informationSHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN
SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the
More informationPatient Group Direction for the Supply of Varenicline (Champix ) by Authorised Community Pharmacists
Patient Group Direction for the Supply of Varenicline (Champix ) This Patient Group Direction (PGD) is a specific written instruction for the supply of varenicline to groups of patients who may not be
More informationPATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine
PHE publications gateway number: PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine For the supply of
More informationEmflaza. (deflazacort) New Product Slideshow
Emflaza (deflazacort) New Product Slideshow Introduction Brand name: Emflaza Generic name: Deflazacort Pharmacological class: Corticosteroid Strength and Formulation: 6mg, 18mg, 30mg, 36mg tablets; 22.75mg/mL
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationConsultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off
Policy For The Adjustment Of Insulin Injections By Paediatric Diabetes Specialist Nurses/Community Paediatric Nurses Diabetes Working With Children Within NHS Grampian Co-ordinators: Lead Paediatric Diabetes
More informationpatient group direction
REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic
More informationGG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Active immunisation
More informationPatient Group Direction No. VI 17. Kathy Wakefield/Lisa Murray. General Practices & TRFT. Relevant Clinical Lead
T i:1 Patient Group Direction (PGD) for The Administration of Meningococcal Group C Conjugate Vaccine (Meningitec /NeisVac-C /Menjugate Kit ) by Registered Nurses employed or commissioned by NHS Rotherham
More informationHEPATITIS A + TYPHOID VACCINE
GG&C PGD ref no: 2017/1522 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Indicated for active immunisation
More informationSAMPLE. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie
Patient Group Direction for the Supply or Administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate Vaccine (Infanrix-IPV-HIB) to children
More informationCALDERDALE PRIMARY CARE TRUST
CALDERDALE PRIMARY CARE TRUST PATIENT GROUP DIRECTION FOR THE SUPPLY AND ADMINISTRATION OF MEDICINES BY NON- MEDICAL PERSONNEL Progestogen-only emergency contraception for use in Community Pharmacies APPROVED
More informationCLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES
National Patient Safety Alert RRR018 Preventing Fatalities From Medication Loading Doses (November 2010) MMCP05 CLINICAL PROTOCOL THE PREVENTION OF FATALITIES FROM MEDICATION LOADING DOSES INTRODUCTION
More informationpatient group direction
SALBUTAMOL v01 1/12 SALBUTAMOL PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner
More informationPharmaceutical Form(s) A clear colourless aqueous solution for intramuscular injection or intravenous infusion in a 1 ml ampoule.
New Zealand Data Sheet SYNACTHEN tetracosactide hexaacetate 250 micrograms/ml solution for injection or infusion TRADE NAME SYNACTHEN i.m./i.v. 250 micrograms/ml solution for injection or infusion. DESCRIPTION
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationpatient group direction
DIAZEPAM (RECTAL) v01 1/8 DIAZEPAM (RECTAL) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationEnter medicine name or company Advanced search >
HOME MEDICINES COMPANIES LATEST UPDATES ABOUT EMC SIGN UP LOG IN Enter medicine name or company Advanced search > Fludrocortisone acetate 0.1 mg tablets Last Updated on emc 09-Dec-2015 View changes Aspen
More information